C. utilis Uricase Cassette Compatibility — Dual-Cassette Koji Multi-Payload Configuration (Computational, comp-011)

The engineering weakness is loss of correct processing, folding, or secretion when a C. utilis uricase sequence is adapted to the Ward-style Aspergillus cassette. COMP-011 does not establish whether the wild-type or mutation-proxy construct succeeds.

Current evidence boundary

UniProt P78609 supplies the wild-type C. utilis uricase sequence. US10815461B2 supplies a set of disclosed mutations, but the exact clinical ALLN-346 parent sequence was not available in the retired artifact. Ward 1995 supplies an Aspergillus secretion precedent (In Vitro); it does not validate this construct.

The retired COMP-011 model inferred codon burden without a planned CDS, mixed wild-type P78609 with a synthetic seven-mutation proxy, mis-mapped glycosylation coordinates, transferred KEX2-family preferences, and turned native-unpaired cysteine annotations into categorical folding and secretion-risk claims. Its MODERATE verdict, codon burden, KEX2 certainty, folding/PDI, glycosylation, secretion-capacity, and exact-ALLN-346 interpretations are invalid. The COMP-011 tombstone is non-runnable.

Research conjecture — mutation-dependent junction processing

Grounded premises: Wild-type P78609 (source: UniProt P78609) and the patent-disclosed mutation set (source: US10815461B2) are distinct sequence objects; the Ward secretion study provides an In Vitro processing precedent for a different payload (PMID 9634791). The clinical parent and the intended A. oryzae CDS remain unverified.

Novel leap: One or more disclosed mutations might alter processing or folding in the Ward-style secretion context even if catalytic selection favored the variant elsewhere. No direct study has tested those mutations in the proposed construct.

Why it matters: A construct-specific effect could distinguish a sequence problem from a platform problem and prevent an invalid generalization from one variant.

Discriminating observation: Define and sequence-verify each construct, then compare wild-type P78609 and the exact mutation proxy for produced termini, intact abundance, folding/assembly, secretion compartment, and retained uricase activity under matched conditions.

The exact clinical ALLN-346 sequence must not be inferred from the patent mutation list. No result here selects a variant, cassette, carrier, tag, or chassis.